1 Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun11, 1620, doi:10.1038/s41467-020-15562-9 (2020).
2 Tomlins, S. A. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia10, 177-188, doi:10.1593/neo.07822 (2008).
3 Katopodis, P. et al. Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19. Int J Oncol57, 533-539, doi:10.3892/ijo.2020.5071 (2020).
4 Kong, Q. et al. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection. Mol Cancer19, 80, doi:10.1186/s12943-020-01209-2 (2020).
5 Bao, R., Hernandez, K., Huang, L. & Luke, J. J. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer8, doi:10.1136/jitc-2020-001020 (2020).
6 Mollica, V., Rizzo, A. & Massari, F. The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future Oncol16, 2029-2033, doi:10.2217/fon-2020-0571 (2020).
7 Trifunovski, A. et al. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience. Pril (Makedon Akad Nauk Umet Odd Med Nauki)41, 5-14, doi:10.2478/prilozi-2020-0018 (2020).
8 Dudka, I. et al. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. BMC Cancer20, 437, doi:10.1186/s12885-020-06908-z (2020).
9 Luo, L. et al. TMPRSS2 Correlated With Immune Infiltration Serves as a Prognostic Biomarker in Prostatic Adenocarcinoma: Implication for the COVID-2019. Front Genet11, 575770, doi:10.3389/fgene.2020.575770 (2020).
10 Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature455, 1069-1075, doi:10.1038/nature07423 (2008).
11 Rousseaux, S. et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med5, 186ra166, doi:10.1126/scitranslmed.3005723 (2013).
12 Okayama, H. et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res72, 100-111, doi:10.1158/0008-5472.Can-11-1403 (2012).
13 Der, S. D. et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol9, 59-64, doi:10.1097/jto.0000000000000042 (2014).
14 Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics14, 7, doi:10.1186/1471-2105-14-7 (2013).
15 Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A102, 15545-15550, doi:10.1073/pnas.0506580102 (2005).
16 Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res45, D353-d361, doi:10.1093/nar/gkw1092 (2017).
17 Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics9, 559, doi:10.1186/1471-2105-9-559 (2008).
18 Takahashi, H. et al. Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers (Basel)12, doi:10.3390/cancers12051221 (2020).
19 Miranda, A. et al. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proc Natl Acad Sci U S A116, 9020-9029, doi:10.1073/pnas.1818210116 (2019).
20 Li, W. Y. et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer19, 145, doi:10.1186/s12885-019-5331-z (2019).
21 Comprehensive molecular profiling of lung adenocarcinoma. Nature511, 543-550, doi:10.1038/nature13385 (2014).
22 Ferguson, L. R. et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol35 Suppl, S5-s24, doi:10.1016/j.semcancer.2015.03.005 (2015).
23 Palmieri, G. et al. Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? J Transl Med15, 17, doi:10.1186/s12967-017-1119-6 (2017).
24 Smith, J. C. & Sheltzer, J. M. Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. Elife7, doi:10.7554/eLife.39217 (2018).
25 Knijnenburg, T. A. et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep23, 239-254.e236, doi:10.1016/j.celrep.2018.03.076 (2018).
26 McKinney, J. A. et al. Distinct DNA repair pathways cause genomic instability at alternative DNA structures. Nat Commun11, 236, doi:10.1038/s41467-019-13878-9 (2020).
27 Eischen, C. M. Genome Stability Requires p53. Cold Spring Harb Perspect Med6, doi:10.1101/cshperspect.a026096 (2016).
28 Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature501, 338-345, doi:10.1038/nature12625 (2013).
29 Li, M., Zhang, Z., Li, L. & Wang, X. An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles. Commun Biol3, 505, doi:10.1038/s42003-020-01230-7 (2020).
30 Walker, C., Mojares, E. & Del Río Hernández, A. Role of Extracellular Matrix in Development and Cancer Progression. Int J Mol Sci19, doi:10.3390/ijms19103028 (2018).
31 Patel, S. P. & Kurzrock, R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther14, 847-856, doi:10.1158/1535-7163.Mct-14-0983 (2015).
32 Zang, R. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol5, doi:10.1126/sciimmunol.abc3582 (2020).
33 Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell181, 271-280.e278, doi:10.1016/j.cell.2020.02.052 (2020).
34 Bestle, D. et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance3, doi:10.26508/lsa.202000786 (2020).
35 Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science362, doi:10.1126/science.aar3593 (2018).
36 Stopsack, K. H., Mucci, L. A., Antonarakis, E. S., Nelson, P. S. & Kantoff, P. W. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov10, 779-782, doi:10.1158/2159-8290.Cd-20-0451 (2020).
37 Chae, Y. K. et al. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Clin Lung Cancer20, 88-96.e86, doi:10.1016/j.cllc.2018.09.008 (2019).
38 Kinoshita, T. et al. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. Eur J Cancer86, 15-27, doi:10.1016/j.ejca.2017.08.026 (2017).